Background: The amelioration of behavioral and neuropathological deficits in mice expressing caspase-6-resistant (C6R) mutant huntingtin (mhtt), despite the presence of an expanded polyglutamine tract, highlights proteolysis of htt at the 586aa caspase-6 (casp6) site may be an important mechanism in the pathogenesis of Huntington disease (HD). One possible explanation of these effects is that C6R mhtt could act as a dominant negative on mhtt. Objective and Methods: To determine if the neuroprotective effect observed in the C6R mice is due to dominant negative effects, we crossed the C6R mice to the YAC128 HD mouse model to generate mice expressing both caspase-cleavable and C6R mhtt (YAC/C6R) concurrently and assessed previously defined behavioral and neuropathological endpoints. Results: Our results demonstrate that YAC/C6R animals exhibit similar motor abnormalities and learning deficits as the YAC128 mice. Neuropathological analysis reveals a significant decrease in brain weight and striatal volume in the YAC/C6R mice comparable to the YAC128 mice. In contrast, and similar to previous findings, C6R mice demonstrate preserved brain weight and striatal volume. As expected, body weight is significantly increased in the YAC/C6R mice due to the increased levels of htt.
INTRODUCTION
Huntington disease (HD), caused by an expanded CAG repeat in the gene encoding huntingtin (htt), * Correspondence to: Michael R. Hayden, Centre for Molecular Medicine and Therapeutics, University of British Columbia, 980 West 28th Avenue, Vancouver, BC V5Z 4H4, Canada. Tel.: +1 604 875 3535; Fax: +1 604 875 3819; E-mail: mrh@cmmt.ubc.ca. is a fatal neurodegenerative disease characterized by progressive deterioration of cognitive and motor function [1] . There is strong evidence that apoptosis plays a role in the neurodegeneration observed in HD [2] [3] [4] [5] . Apoptosis is a genetically programmed form of cell death that utilizes caspases, a family of cysteine proteases that are activated by proteolytic processing and dimerization. Increased DNA fragmentation and typical apoptotic, TUNEL positive cells have been detected in human HD brain [4, 6] . Furthermore, activation of caspases is observed in human and murine HD brain and the pro-apoptotic protein Bax is increased compared to controls [2] [3] [4] . Indeed, htt was the first neuronal caspase substrate identified [7] . Proteolytic cleavage of htt by caspases releases an amino terminal fragment containing the glutamine tract [7] [8] [9] [10] [11] . Expression of htt fragments containing an expanded polyglutamine repeat are toxic in vitro and in vivo [12, 13] , and accumulation of N-terminal truncated products of htt are observed in postmortem brain tissue from HD subjects, as well as in mouse models of HD [9, 10, 14] .
Numerous caspase substrates have active roles in apoptosis, in particular as a result of the fragments generated. The stress-induced generation of caspasecleaved proteolytic fragments has been shown to trigger toxicity and amplify the cell death response in several experimental paradigms [15] [16] [17] [18] [19] [20] [21] [22] [23] . For example, caspase-dependent cleavage of CDC25A generates an active fragment that activates cyclin-dependent kinase 2 during apoptosis [16] and casp6-cleavage of NF-ß generates a pro-apoptotic fragment which induces cell death [15] and disrupts the pro-survival signaling pathway. In HD, the 586aa htt fragment is observed in affected brain regions and importantly, murine models expressing the 586aa mhtt fragment develop neurological abnormalities similar to those observed in other HD mouse models [9, [24] [25] [26] [27] . In AD brain tissue, p97, a valosin containing ubiquitin dependent ATPase, is cleaved by casp6 and the resultant fragment impairs the proteasome and destabilizes endogenous p97 [18] . Of interest, casp6 cleaved tau is observed in AD and HD brain, and levels of casp6 cleaved tau in human brain inversely correlate with global cognitive scores [2, 28, 29] .
Similar to htt, APP is also cleaved by caspases during apoptosis [30] [31] [32] . Two casp6 cleavage sites within APP (at residues 653 and 664) have been identified in vitro [31, 32] . Cleavage of APP at the 664aa site has been detected in early-stages of disease in human AD brain tissue [33, 34] and is a necessary requirement for nuclear p21-activated kinase signalling [35] , and deficits in synaptic transmission and learning in AD mouse models [36] .
Additional evidence supporting the role of caspasegenerated fragments in the pathogenesis of neurodegenerative diseases derives from studies on the caspase resistant form of a caspase substrate. Expression of a mutation that eliminates cleavage at the 586aa site of mutant htt [i.e. Casp6-resistance (C6R) mhtt] is sufficient to preserve striatal volume and cognitive and motor function in a yeast artificial chromosome (YAC) model of HD [2, 9, 37, 38] , as well as preventing alterations in extrasynaptic NMDA receptor activation [39] . These results are compatible with proteolysis of htt at the 586aa cleavage site being a important step in the pathogenesis of HD. Furthermore, in contrast to the active casp6 observed in the brains of pre-symptomatic and early-grade human HD patients as well as murine HD models, in vivo expression of C6R mhtt attenuates casp6 activation [2] .
Inhibiting cleavage of APP at residue 664 also provides partial rescue from behavioural deficits and neuropathology in an AD mouse model [34] [35] [36] [40] [41] [42] , providing proof-of-principle for the importance of cleavage at this particular site within APP in the pathogenesis of AD. Furthermore, activation of casp6 and cleavage of a number of casp6 substrates is observed in early-stage AD human brain [18, 28-30, 43, 44] .
In general, inhibiting the cleavage of a caspase substrate has been shown to confer protection in numerous experimental paradigms [2, 9, 11, 15, 20, [37] [38] [39] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] . An unresolved question is whether the neuroprotection observed upon expression of a caspase-resistant substrate, such as C6R mhtt, is due to dominant-negative effects such as suppression of mhtt expression and/or casp6 activation. Prior to assessing this, it is important to rule out other factors that may influence the phenotype or lack thereof in the C6R mice. Studies in HD patients and mouse models reveal a clear relationship between levels of mhtt and the severity of the HD phenotype. If mhtt transgene expression levels and/or CAG size were decreased in the C6R mice compared to the YAC128 lines this may suggest they are protected as they would present with a less severe phenotype. The C6R mice have 13CAGs more than the YAC128 line [9] , thus, the C6R lines do have a CAG size that is at least as large as the control YAC128 lines. Furthermore we have previously shown that transgene levels in the C6R mice are most comparable to YAC128 line HD53 [9] . We have extended that analysis here and include copy number and validation of RNA and protein transgene expression levels in a new cohort of YAC mice.
If the neuroprotection observed in C6R mice reflects a dominant-negative effect such as suppression of mhtt expression then similar protection and amelioration of HD-related phenotypes may be expected in mice expressing both caspase-cleavable and C6R mhtt. In order to address this question we crossed the YAC128 mice to the C6R mice to generate mice expressing both caspase-cleavable and C6R mhtt (YAC/C6R) and assessed previously defined behavioral and neuropathological endpoints.
MATERIAL AND METHODS

HD transgenic mice
YAC128 and C6R (lines C6R7 and C6R13) mice were generated as described [9, 57] . All murine tissues harvested according to UBC Animal Protocol A07-0106.
Real-time quantitative PCR to determine HTT transgene DNA level
Mouse genomic DNA was extracted from tail samples and 0.08 ng of the genomic DNA used in a final volume of 10 ul with Power SYBR Green PCR Master Mix (ABI). Human-specific huntingtin primers and mouse-specific beta-actin primers as described [58] were used at the final concentration of 100 nM. Comparative Ct Assay was performed using ABI 7500 Fast Real-Time PCR System under default condition. The relative transgene DNA levels were normalized to mouse ␤-actin.
Real-time quantitative RT-PCR to determine transgenic mRNA expression level
Total RNA was extracted from mouse cortex with RNeasy Mini Kit or RNeasy Micro Kit (Qiagen) and treated with Amplification Grade DNaseI (Invitrogen). First-strand cDNA was prepared from 1 g of total RNA using SuperScriptIII First-Strand Synthesis System (Invitrogen). cDNA from 2 ng of total RNA was used in a final volume of 10 l with Power SYBR Green PCR Master Mix (ABI). Comparative Ct Assay was performed using ABI 7500 Fast Real-Time PCR System under default condition. All samples were run in triplicate. mRNA expression levels of target genes were normalized to ␤-actin. Human specific HD and mouse ␤-actin primers were as described [58] .
Protein analysis and western blotting
Murine tissue protein lysates were prepared as described previously [2] . Immunoblots for huntingtin were probed using MAB1574 (1 : 2000, Chemicon) or MAB2166 (1 : 2000, Chemicon)and Calnexin (1 : 10,000, Sigma) antibodies. All immunoblotswere prepared following standard procedures and used infraredlabeled secondary antibodies, Immobilon-PVDF-FL membranes and the Li-Cor Odyssey Infrared imaging system (BioSciences). Quantitative analysis of immunoblotting was based on the integrated intensity from Li-Cor Odyssey software (v2.0). Calnexin was used as loading control.
FRET assay for the quantification of soluble mHtt
Detection of mutant htt in plasma samples was performed as described previously [59] . Monoclonal BKP1 antibody raised against the htt N-terminus [60] and monoclonal MW1 antibody raised against the expanded polyglutamine tract of mHtt were labelled with terbium or D2 (Cisbio Bioassays) fluorescent tags, respectively. Antibodies were mixed in 50 mM NaH 2 PO 4 , 0.1% bovine serum albumin (BSA), and 0.05% Tween 20 at 1 ng/l BKP1-terbium and 10 ng/l MW1-D2. To each 20 l plasma sample, 2 l of antibody master mix was added in a white 384 well plate, and plates were measured with a xenon lamp Victor Plate Reader (Perkin Elmer) after excitation at 340 nm (time delay 50 ms, window 200 ms). The signal measured at 615 nm resulted from the emission of the terbium-labeled antibody and was used for normalization of potential signal artefacts. The htt-specific signal at 665 nm resulted from emission of the D2-labeled antibody after time-delayed excitation by the terbium. The relative mhtt concentration is represented by the 665/615-nm ratio.
Rotarod
Motor coordination and learning were assessed by accelerating rotarod (UGO Basile) testing. Two month old mice were trained for 3 consecutive days during 3, 120 s trials per day with a 2 hour inter-trial interval. Mice falling from the rod were returned, to a maximum of 10 falls/trial. The time to first fall and number of falls per trial were recorded, and the average of the three trials was scored. For longitudinal rotarod assessment, 2 and 4 month old mice were tested on a rod accelerating from 5 to 40 RPM over 300 seconds. Latency to the first fall was recorded and the average of 3 trials was scored.
Novel object location
To assess spatial learning by preference for a known object in a novel location, 4 month old mice were placed in the lower left corner of a 50 × 50 cm open grey acrylic box with 20 cm sides and allowed to acclimate for 5 minutes. Mice were then removed from the box for a 5 min ITI and two different novel objects are placed in the upper two corners of the box, far enough from the sides so as to not impede movement around the outer edge (7 cm). Mice were reintroduced to the box in the lower left corner and recorded for 5 min by a ceiling mounted video camera, during which the frequency and duration of investigations of the objects was scored by Ethovisionxt 7.0 animal tracking software. Mice were then removed from the box for a 5 min ITI, and the object at the top right corner of the box was moved to the lower right corner of the box. Mice were then reintroduced to the box and recorded for 5 min during which the frequency and duration of investigations of the objects was scored. The percentage of the investigations to the object in the new location was computed.
Neuropathology
All quantitative analysis was done blind with respect to genotype as described previously [9, 57] . Briefly, mice were weighed then terminally anesthetized by intraperitoneal injection of 2.5% avertin and perfused with 3% paraformaldehyde/0.15% glutaraldehyde in PBS. The brains were stored in 3% paraformaldehyde for 24 h at 4 • C then removed and stored in PBS + Azide. Mouse brains were weighed and then cut using a vibratome and coronal sections (25 m) spaced 200 m a part through out the striatum were stained with Neu N antibody (Chemicon, Teme-cula, CA) at 1 : 1000 dilution. Biotinylated secondary antibodies (Vector) were used at 1 : 1000 prior to signal amplification withan ABC Elite kit (Vector) and detection with DAB (Pierce, Rock-ford, IL).
The perimeter of the striatum for each section was traced using Stereo Investigator 10 software (Microbrightfield, Williston, VT, USA). Striatal volume was determined using the Cavalieri principle where the area of each striatum per section was summed and multipled by the section thickness (25 microns) and section sampling interval (every eighth section) as previously described [61] .
Immunohistochemistry
Mouse brains were fixed and sectioned as described above then immunoassayed with DARPP-32. Quantification of DARRP-32 was performed on 25 m free-floating sections from WT, YAC128, C6R and YAC/C6R mice. The primary antibody used was mouse anti-DARPP32, #C24-6a (gift from Dr. Paul Greengard and Dr. HughHemming; 1 : 20,000). Sections incubated without primary antibody served as controls. Sections were washed and incubated with horseradish peroxidase (HRP) conjugated secondary antibody (1 : 500, Jackson ImmunoResearch Laboratories). Staining was visualized using DAB and counter stained with 0.5% cresyl violet. Sections were photographed using a Zeiss Axioplan 2 microscope and Cool snap HQ Digital CCD camera (Photometrics). The amount of DARPP32 was determined using Meta Morph software version 6.3 (Universal Imaging Corporation). Labeling was identified using constant threshold levels for all images and analyzed using "integrated morphometry. Relative levels of staining were calculated as the sum of the integrated optical density (IOD) for each image divided by the area of the region selected then multiplied by the sampling interval (8) and section thickness (25m). No staining was observed in a negative control without primary antibody.
Assessment of nuclear huntingtin and inclusions
WT, YAC128, C6R and YAC/C6R lines were immunoassayed with the polyclonal antibody EM48 to assess for the presence of nuclear htt and inclusions as described previously [9] using EM48 at 1 : 2000 and DAB as the chromogen (Vector). Htt inclusions were defined as EM48 positive punct a visible at the light microscope levels. Photographs were taken on a light microscope (Zeiss) using 100 objective. The number of cells containing huntingtin inclusions were quantified from EM48 stained sections using stereological techniques. Briefly, every 24th section spanning from Bregma 1.42 mm to −0.82 mm with a total of four sections per mouse were utilized in the analysis. Striatum and cortex in each section were delineated at low magnification (2.5×). Cells that were considered positive for htt inclusions were designated as cells containing intense, darkly stained particulates. Total positively stained cells were estimated using a 40× objective and the Fractionator Probe with a counting frame of 25 × 25 and grid size of 250 × 250 for striatum and 500 × 500 for cortex of the stereology software (StereoInvestigator 10; MBF Bioscience; Williston, VT). Analysis was performed with the investigator blind to genotype.
Statistical analysis
Statistical analysis was done using Student's t-test, one-way and two-way ANOVA (in cases of significant effect of genotype, post-hoc comparisons between genotypes were performed using Bonferroni). p values, SEM, means and standard deviations were calculated using Graphpad Prism version 5.0. Differences between means were considered statistically significant if p < 0.05.
RESULTS
Transgene levels in YAC mice
As the phenotype of HD is significantly influenced by levels of expression of mhtt [58, [62] [63] [64] [65] [66] , it is essential to control for this parameter in order to determine if C6R mhtt can rescue the toxic effects of caspase-cleavable mhtt in vivo. We therefore first re-assessed which YAC128 line has transgene expression levels most similar to the C6R mice. In order to match transgene expression in C6R murine brain tissue to the most appropriate YAC128 line we assessed copy number, mRNA and protein transgene levels in the C6R (C6R7 and C6R13) and YAC128 (HD54, HD55 and HD53) lines of mice (n = 3, agematched). A comparison of HD gene copy number in the YAC128 and C6R lines demonstrates that transgene copy number in the C6R mice is most similar to the previously described YAC128-HD53 mice (ANOVA p = 0.0001, Fig. 1A ). Assessment of mhtt mRNA levels demonstrates that cortical transgene mRNA expression in the C6R mice are most similar to the YAC128-HD53 mice and higher than YAC128-HD55 as found previously [9, 67] (ANOVA p = 0.0001; YAC128-HD53 vs. C6R7 p > 0.05; YAC128-HD55 vs. C6R7 p < 0.001; YAC128-HD54 vs. C6R7 p < 0.001; Fig. 1B) . Immunoblotting with several different htt antibodies reveals that full-length mhtt levels in C6R cortex are intermediate between HD53 and HD55 transgene levels (Fig. 1C-D) . However, as proteolysis of htt in the C6R and YAC128 brain tissue will affect full-length mhtt levels this may not provide an accurate estimation of true levels of total mhtt. This causes difficulties in determining total transgene protein levels in these mice. We therefore assessed soluble htt levels in plasma where protease activation may be expected to be at a minimum. Using this method demonstrates that mhtt levels in C6R vs YAC128-HD53 are not significantly different (Fig. 1E , n = 12, p = 0.68). However, YAC128-HD53 and HD55 do show a significant difference in soluble htt levels (Fig. 1E , n = 12, p = 0.03) and there is a trend towards a decrease in soluble mhtt levels in HD55 compared to C6R (p = 0.06). We also assessed body weight in the YAC128 and C6R lines as levels of mhtt have been shown to influence this parameter [68, 69] . Analysis of body weight at 12 months of age in the various lines demonstrates that the C6R mice are most closely matched to YAC128-HD53 line (n = 15, female, ANOVA p = 0.001; C6R vs. HD53 p > 0.05; C6R vs. HD55 p < 0.01; HD53 vs. HD55 p < 0.01; Fig. 1F ). The C6R7 mice were chosen, based on the general analysis, for further investigation to cross to the mutant htt line. Similarly, based on the above results, the YAC128-HD53 line was chosen as the YAC128 line for the cross.
Generation and characterization of YAC/C6R mice
Using breeding strategies with YAC128-HD53 and C6R7 mice, we developed a YAC/C6R line. Mhtt mRNA levels in the cortex of YAC/C6R mice are higher than either YAC128 or C6R cortical tissue as expected (n = 3, ANOVA p = 0.015; YAC/C6R vs. YAC128 p < 0.05; YAC/C6R vs. C6R p < 0.05; Fig. 2A ). Assessment of full-length mhtt protein levels demonstrates that YAC/C6R cortex contains ∼25% (using 1C2 htt antibody, n = 3, Fig. 2B ) or ∼49% (using MAB2166 htt antibody, n = 3, Fig. 2C , trend towards increased htt in YAC/C6R, ANOVA p = 0.09) increase in levels of mhtt vs. YAC128 mice. We also determined htt levels in the plasma of the cross mice. Our results demonstrate that mhtt levels in the plasma of YAC/C6R mice are significantly higher than YAC128 (42% increase) or C6R (41% increase) mhtt plasma levels (n = 14, ANOVA p = 0.0008, YAC128 vs. YAC/C6R p < 0.01; C6R vs. YAC/C6R p < 0.05, Fig. 2D ). Evaluation of body weight in all genotypes from the cross (WT, YAC128, C6R and YAC/C6R) reveals that female body weights in the transgenic mice at 3 and 12 month of age demonstrate a significant increase compared to WT (3 months: ANOVA p = 0.0001, Fig. 3A ; 12 months: ANOVA p = 0.0001, Fig. 3B) . No difference in male body weights were observed at 3 months of age in the transgenic YAC vs. WT mice (Fig. 3C) . However, at 12 months of age, male body weights in the YAC mice are significantly higher than WT (ANOVA p = 0.0001, Fig. 3D ).
Motor abnormalities and spatial learning deficits in YAC/C6R mice
As previously shown, YAC128 mice demonstrate motor abnormalities, depression and cognitive deficits including difficulties in changing strategies, delayed platform finding and impaired spatial learning [37, 57, [70] [71] [72] . To determine if YAC/C6R mice demonstrate Mhtt mRNA levels in the cortex of YAC/C6R mice are higher than either YAC128 or C6R cortical tissue (n = 3, ANOVA p = 0.015; YAC/C6R vs.YAC128 p < 0.05; YAC/C6R vs. C6R p < 0.05). B) Assessment of full-length mhtt protein levels demonstrates that YAC/C6R cortex contains ∼25% (1C2 htt antibody, n = 3) or C) ∼49% (MAB2166 htt antibody, n = 3) increase in levels of mhtt vs. YAC128 mice. D) Mhtt levels in the plasma of YAC/C6R mice are significantly higher than YAC128 (42% increase) or C6R (41% increase) mhtt plasma levels (n = 14, ANOVA p = 0.0008, YAC128 vs. YAC/C6R p < 0.01; C6R vs. YAC/C6R p < 0.05). *p < 0.05; **p < 0.01.
behavioral deficits we assessed rotarod performance and preference for a novel object in WT, YAC128, YAC/C6R and C6R cohort of mice. At 2 and 4 months of age rotarod deficits are observed in mice expressing YAC/C6R mhtt (2 months ANOVA p = 0.009, WT vs. YAC/C6R p < 0.01, C6R vs. YAC/C6R p < 0.05, Fig. 4A ; 4 months ANOVA p < 0.019, WT vs. YAC/C6R p < 0.05, Fig. 4B ; body weight of behavior tested mice Fig. 4D-G) . To assess spatial learning by preference for a known object in a novel location, 4 month old mice were habituated to an open field for 5 minutes. Mice were then removed from the box for a 5 min inter-trial interval (ITI) and then exposed to two novel objects in the open field (T1). Investigations of the novel objects were scored. Mice were then removed from the box for a 5 min ITI, and the object at the top right corner of the box was moved to the lower right corner of the box. The mice were then reintroduced to the box. Investigation of each object was scored for 5 min and the percentage of the investigations to the target object, the one in the novel location, determined (T2). A score of 50% indicates no preference. WT and C6R mice display a preference for the novel object location (two-way ANOVA, genotype p = 0.04; F = 2.73, Bonferroni post hoc C6R trial 1 vs. trial 2 p < 0.05; WT not significant by post hoc but are by t-test p = 0.017, Fig. 4C ). However, YAC128 and YAC/C6R mice display no preference in either trial indicating impaired spatial learning (Fig. 4C) . 
YAC/C6R mice demonstrate striatal neurodegeneration
In order to examine the effect of concurrently expressing both caspase-cleavable mhtt and C6R mhtt in vivo on the selective neuropathological phenotype observed in the YAC128 mice, we assessed brain weight and striatal volume in WT, YAC128, C6R and YAC/C6R mice at 12 months of age (n = 11). We have previously defined striatal volume loss as our most robust morphologic endpoint in the YAC128 mice [9, 57, 70] . As expected, YAC128 brain weights are significantly lower than WT controls at 12 months of age (WT = 0.37 ± 0.01 g, YAC128 = 0.35 ± 0.01 g, p = 0.02; Fig. 5A ). Similarly, striatal volume is reduced by 12% in YAC128 mice relative to WT controls (WT = 12.7 ± 0.11 mm 3 , YAC128 = 11.2 ± 0.15 mm 3 ; p = 0.003; Fig. 5B ). By contrast, C6R mice do not exhibit a significant reduction in brain weight (C6R = 0.37 ± 0.01 g, p = 0.35; Fig. 5A ) or striatal volume at 12 months compared to WT mice (C6R = 12.3 ± 0.07 mm 3 , p = 0.33; Fig. 5B ) as found previously [9] . In mice expressing YAC/C6R mhtt a significant decrease in brain weight (YAC/C6R = 0.35 ± 0.01 g, p = 0.007; Fig. 5A ) and striatal volume is observed (YAC/C6R = 10.7 ± 0.16 mm 3 , p = 0.0019; Mice were then removed from the box for a 5 min ITI and then exposed to novel objects in the open field (T1). Investigations of the novel objects was scored. Mice were then removed from the box for a 5 min ITI, and the object at the top right corner of the box moved to the lower right corner of the box. Mice were then reintroduced to the box and recorded for 5 min during which the frequency and duration of investigations of the objects was scored (T2). A score of 50% indicates no preference. WT and C6R mice display a preference for the novel object location (two-way ANOVA, genotype p = 0.04; F = 2.73, Bonferroni post hoc C6R trial 1 vs. trial 2 p < 0.05; WT not significant by post hoc but are by t-test p = 0.017). In contrast, YAC128 and YAC/C6R mice display no preference in either trial indicating impaired spatial learning. N = 16 WT mice, 14 YAC128 mice, 12 YAC/C6R mice and 20 C6R mice. Evaluation of body weight in mice used in the early behavior studies (WT, YAC128, C6R and YAC/C6R) reveals that female body weights in the transgenic mice at D) 2 and E) 4 month of age demonstrate a significant increase compared to WT (2 months: ANOVA p < 0.0001; 4 months: ANOVA p < 0.0001). F) No difference in male body weights were observed at 2 months of age in the transgenic YAC vs. WT mice. G) At 4 months of age, there is a trend towards increased male body weight in the YAC mice vs. WT (ANOVA p = 0.08). *p < 0.05; **p < 0.01; ***p < 0.001. brain: ANOVA p = 0.003; striatal volume ANOVA p = 0.0012). No difference in cerebellar weight was observed in any of the transgenic mice compared to WT (Fig. 5C ).
Decreased levels of DARPP-32 and increased nuclear htt in YAC/C6R mice
Levels of DARPP-32 are decreased in HD human postmortem brain tissue and in several HD murine models including the YAC128 mice [38, 73, 74] . We therefore assessed levels of DARPP-32 to further validate the neurodegeneration observed in the YAC/C6R mice (n = 7). As found previously, YAC128 mice demonstrate a significant decrease in striatal DARPP-32 levels vs WT (p = 0.04, Fig. 6A and B) . A trend towards decreased DARPP-32 levels is observed in the YAC/C6R mice (p = 0.11, Fig. 6A and B ). In contrast, mice expressing C6R mhtt do not demonstrate a decrease in striatal DARPP-32 levels vs. WT (p = 0.78, Fig. 6A and B) , similar to previous results [38] .
Relocation of htt to the nucleus and formation of inclusions area hallmark of the human disease and are present in the brains of human patients [75, 76] . However, since the initial discovery of htt inclusions, there has been continued controversy over the role of htt inclusions/aggregates in the pathogenesisof the disease. Mhtt does have a dose dependent effect on the time course, frequency of htt inclusions and nuclear localization of htt [58] . Similar to HD human post mortem brain tissue, YAC128 mice demonstrate intranuclear striatal inclusions albeit at a low level and late in the phenotype [57, 77] . In contrast to the YAC128 mice, YAC128-shortstop mice exhibit widespread htt inclusions yet do not manifest an HD-related phenotype [77] . Assessment of EM48 immunostaining in the YAC/C6R striatum (Fig. 7A,  D) and cortex (Fig. 7B, E ) reveals an increase in nuclear htt and inclusions compared to YAC128 or C6R mice (striatum, n = 3, ANOVA p = 0.0004; cortex, n = 3, ANOVA p = 0.002) consistent with the increased expression levels of mhtt in these mice. Expression levels of EM48 in YAC128 and C6R mice were as found previously [9, 67] .
DISCUSSION
In this study our goal was to determine whether the neuroprotection observed in mice expressing C6R mhtt is due to dominant negative effects. This was an experiment, in the most classical sense, of a dominant negative mutation study (inserting a mutation or an aa alteration in a protein to elucidate the function of a protein and determine if over expression of the altered polypeptide disrupts the function of the wild type gene) [78] . It is important to clarify that in this experiment we are comparing the effect of mutagenesis of the 586aa site on the function of mutant huntingtin. Motor abnormalities and cognitive deficits, as defined by rotarod performance and preference for a known novel object in a novel location, and striatal neurodegeneration are present in mice concurrently expressing C6R and caspase-cleavable mhtt. This evidence suggests that dominant negative affects do not account for the lack of an HD phenotype in the C6R mice.
In such a study as we describe here, it is first important to rule out other factors that may influence the lack of an observable phenotype in the C6R mice. The phenotype of HD is influenced by mhtt levels and CAG size. Neuroimaging results demonstrate more extensive and severe progressive brain atrophy in the homozygotes and analysis of HD stage (grade) and mean duration showed a shift to the left in the HD homozygotes compared to the heterozygotes individuals [62] . Furthermore, we have demonstrated that onset and progression of the HD phenotype in the YAC128 mouse models is directly modulated by levels of mhtt [58] . Studies in other HD models also support a mhtt dosage effect on the phenotype [64, 79, 80] . HD knock-in mice demonstrate earlier onset of nuclear htt fragment accumulation and a more severe behavioral deficit in the homozygote [81, 82] . In addition to other poly (CAG) disorders (including DRPLA, SCA2, SCA3, SCA6, SCA17), dosage effects are also observed in familial hypercholesterolemia, Parkinson disease and Pelizaeus-Mersbacher disease [83] [84] [85] [86] [87] [88] [89] . If mhtt transgene levels were decreased in the C6R mice compared to the YAC128 lines this may erroneously suggest they are protected. Using several markers of transgene expression levels we demonstrate that the C6R mice contain mhtt transgene levels comparable to the YAC128-HD53 line. Furthermore, we have previously demonstrated that HD phenotypes are also present in the lower mhtt expressing lines YAC128-HD55 and HD54 [58] . This evidence demonstrates that dosage effects are not responsible for the neuroprotection observed in the C6R mice.
CAG size is also a critical determinant of the severity of the HD phenotype. Indeed, several neurodegenerative diseases, including spinal bulbar muscular atrophy, dentatorubralpallidoluysian atrophy, Machado-Joseph disease among others are caused by a CAG expansion in their respective protein and a correlation observed between CAG tract length and severity of disease [ [90] [91] [92] . In HD, correlations between CAG repeat length and mitochondrial ADP uptake [93] , striatal active casp6 levels [2] and body weight [94] are also detected. As the C6R mice contain a larger CAG size then the YAC128 lines [9] this does not account for the lack of a phenotype in the C6R mice and rather provides additional evidence that cleavage at the 586aa site in mhtt is an important event in the pathogenesis of HD. Another factor, which may influence the lack of a phenotype in the C6R mice, is if the mutated 586aa IVLD site in mhtt (and now present as IVLA in the C6R mice) has altered the conformation of htt and there by altered its function. However, this would appear unlikely as C6R mhtt can rescue the embryonic lethality observed in htt-/-mice demonstrating that mutagenesis of the caspase sites in mhtt does not impair htt function in vivo during development [9] . Furthermore, body weight patterns in mice overexpressing htt (either wild type htt, caspase-cleavable or C6R mhtt forms) are similar [68, 69] .
In general, much of the knowledge on the mechanisms underlying protein function are derived from gene knock out studies and characterization of artificial or natural occurring alternative and/or mutant forms of a protein. Whereas dominant negative studies in the past have used alternative forms of the wild type protein in order to investigate the function of the protein, here we compared alternative forms of the mutant, polyglutamine expanded, htt protein. Mutating the 586aa IVLD site in mhtt to IVLA and characterization of mice expressing C6R mhtt has provided insights into the underlying neurotoxic mechanisms of caspasecleavable mhtt [2, 9, [37] [38] [39] 67 ]. An in vivo comparison of mice expressing caspase-cleavable mhtt compared to mice expressing C6R mhtt demonstrates alteration of the IVLD site in mhtt has shifted the neurotoxicity of mhtt towards neuroprotection. In the present experiment we wished to determine if the HD phenotypes, observed in mice expressing caspase-cleavable mhtt, are altered with the concurrent expression of mhtt that expresses a mutation at the 586aa site (D586A) in order to rule out dominant negative effects. A potential caveat of the present study is that YAC128 homozygotes were not used as the control line in order to more effectively control for levels of transgene expression in the YAC/C6R mice. Both naturally occurring and artificially constructed dominant negative mutations have been described. The end effect is disruption and/or inactivation of the wild type gene product. In some cases it is a truncated version of the protein that antagonizes the function of the full-length form. Examples include proteolytic cleavage of NF-ß and/or NR2A. In the case of NF-ß, caspase cleavage generates a transcriptionally inactive p65 molecule still able to bind DNA [15] . Similarly, calpain mediated cleavage of NR2A results in a truncated fragment that is stable and able to interact with NR1 but lacks the structural domain required for scaffolding and downstream signaling [23] . Several diseases are due to antimorphic or dominant negative mutations and include familial neurohypophyseal diabetes insipidus, a number of endocriopathies and marfan syndrome among others [95] [96] [97] . Dominant negative effects have also been described in HD. EM48+ inclusions are only observed in the presence of mhtt and thus are markers of the disease in human HD brain and in acute and chronic models of the disease [57, 76, 98] . As wild type htt is sequestered in the inclusions it has been suggested that expression of mhtt may antagonize wild type htt function [99] .
It is important to note that in vivo expression of C6R mhtt, rather than demonstrating neurotoxicity as observed with caspase-cleavable mhtt, appears to demonstrate similar neuroprotective properties as wild type htt. Indeed, similar resistance to excitotoxic stress and staurosporine treatment are observed in neurons expressing C6R mhtt or YAC18 wild type htt [9, 63, 73] . Furthermore, while phosphorylation levels of htt are decreased in YAC128 striatal tissue, levels are similar in C6R and YAC18 brain tissue [38] . While the mechanism(s) underlying the neuroprotective phenotype in mice/neurons overexpressing wild type htt is currently unknown, a role for htt as a caspase inhibitor has been demonstrated [100, 101] . Interestingly, in vivo expression of C6R mhtt also attenuates caspase activation [2] . However the result of the present study would suggest that C6R mhtt is neuroprotective not because mutation of the IVLD site (D586A) has conferred novel properties to this form of mhtt (i.e. caspases inhibition and that C6R mhtt is acting as a caspase sink). However, a caveat of this study is that it cannot be ruled out that caspase-cleavable mhtt is more toxic than C6R mhtt is neuroprotective. If caspase-cleavable mhttt has increased kinetics, of as an example, casp6 activation and/or excitotoxic signaling pathways, this may mask a potentially slower rate of neuroprotective kinetics of C6R mhtt (i.e. caspase inhibition). It is interesting to note that some HD phenotypes, observed in the BACHD mouse model, show rescue on a constitutive casp6-/-background and reduced levels of the 586aa htt fragment as detected by immunohistochemistry [27] . These include rescue of rotarod deficits, decreased ubiquitination of proteins and S830 immunopositive aggregates, an antibody known to correlate with overt clinical phentoptye in several mouse models of HD [102] [103] [104] . Furthermore, increased clearance of mhtt was observed. These data support a clear role for casp6 in HD and indeed in modulating steady state levels of htt.
Using striatal volume as a primary endpoint we show that neurodegeneration is observed in mice expressing both caspase-cleavable and C6R mhtt concurrently. Neuronal dysfunction, as determined by behavior testing, is also observed in the YAC/C6R mice. These data suggest that it is the direct effect of cleaving mhtt at aa586 that results in the neurotoxicity observed in the YAC128 mouse model of HD and that dominant negative effects do not account for the lack of a phenotype in the C6R mice.
